An Overview of Angiosarcoma of the Breast

Angiosarcoma of the breast is an uncommon type of breast cancer that begins in the blood or lymphatic vessels within the breast and tends to be aggressive and spread rapidly. Accounting for only around 0.04 percent of breast cancers, there are two types of the disease. Primary angiosarcomas have no known risk factors, and often develop in young women. Secondary angiosarcomas, which are less common, arise after a woman has had radiation therapy to the breast for a different breast cancer.

The most common symptoms of angiosarcomas include bruising, with redness and bruising of the breast, and less commonly, a thickening or lump. Surgery is the treatment of choice for early stage tumors. And unfortunately, recurrence is common. For advanced tumors, chemotherapy and radiation therapy can be ineffective, but clinical trials continue to look at newer treatments that are showing promise.

Also Known As

Breast angiosarcomas may also be referred to as mammary angiosarcomas, hemangiosarcomas of the breast, or lymphangiosarcomas of the breast (if lymph vessels are involved).

carcinoma v. sarcoma
Verywell / JR Bee

Carcinomas vs. Sarcomas

To understand breast angiosarcomas, it's helpful to first distinguish between carcinomas (most breast cancers) and sarcomas.

Most breast cancers that people are familiar with are carcinomas—cancers that begin in epithelial cells, such as those that line the ducts or lobules of the breast.

Sarcomas, in contrast, are derived from myoepithelial cells, cells that make up connective tissues such as bones, muscles, and blood and lymphatic vessels.

The term "angio" means blood, and angiosarcomas are tumors that begin in blood or lymph vessels. Angiosarcomas may occur anywhere in the body, and the majority of these tumors occur in regions other than the breast.

These tumors may be further defined as hemangiosarcomas (which start in blood vessel walls), or lymphangiosarcomas (which start in lymph vessel walls).

Due to the structure of these tissues, and unlike carcinomas, sarcomas do not have a pre-invasive stage, such as ductal carcinoma in situ.

Types of Angiosarcomas

Primary angiosarcomas of the breast account for around 80 percent of breast angiosarcomas and are usually diagnosed in women between the ages of 20 and 40.

Secondary angiosarcomas are often diagnosed in women over the age of 40 and usually occur five to 10 years after radiation therapy for breast cancer for a different, unrelated tumor is completed.


The symptoms of angiosarcoma can vary depending on whether it is primary or secondary, and whether it has metastasized to other regions of the body.

Primary angiosarcoma diagnosed in a person who has never had breast cancer may feel like a thickened area of the breast or an ill-defined lump. In some cases, the nearby skin may turn blue or reddish and appear to have a rash or to be bruised.

Secondary angiosarcoma often presents with an area of redness or a bluish appearance of the breast. There may also be swelling or a mass in the breast. These lumps, unlike many breast cancers, are often painful.

In some cases, the first symptoms of angiosarcoma may occur due to the spread of the cancer in the body. Angiosarcomas are less likely to spread to lymph nodes than more common breast cancers, but tend to spread rapidly to distant regions of the body. Sites of metastasis may include the lungs, liver, bones, skin, other breast, brain, or ovaries.

These tumors have a high rate of recurrence, and may recur locally (in the breast) or in distant regions of the body.

Causes and Risk Factors

The exact cause of angiosarcoma is not known. With primary angiosarcomas, there are also no obvious risk factors for the disease, unlike more common breast cancers.

Secondary angiocarcinomas may occur after radiation, but have also occurred in women who have developed lymphedema as a result of lymph node removal.


A number of different tests may be done in the process of diagnosing a breast angiosarcoma, and the choice of initial testing often depends on the symptoms that are present. The process usually begins with a careful medical history, in particular, noting any prior history of radiation therapy for breast cancer.

Imaging Studies

Radiological studies often done to look for other types of breast cancer may be performed in this case as well, but the appearance of angiosarcoma can be somewhat different.

Imaging includes:

  • Mammogram: Breast masses seen on mammography often have a fuzzy outline. Spiculated masses (lumps with spiky protrusions) are not usually seen.
  • Ultrasound: Angiosarcomas tend to show up well on ultrasound; masses may have a bumpy appearance.
  • Breast magnetic resonance imaging (MRI): A breast MRI is used to confirm results of a mammogram.

A positron emission tomography (PET) scan, bone scan, or CT scan may also be done to look for distant spread.


The type of biopsy chosen often depends on whether the tumor is primary or secondary.

With primary angiosarcomas, a breast biopsy is often needed to define the tumor.

With secondary angiosarcomas, a punch biopsy of the skin is often done. Once tissue is obtained, the disease can still be hard to diagnose, and a second opinion of the pathology report is often recommended.

After a breast angiosarcoma is diagnosed, staging is done by looking at the size of the tumor and degree of spread.


The best treatments for angiosarcoma sometimes differ from those for more common breast cancers.


Either breast conserving surgery (lumpectomy) or aggressive surgery (mastectomy) may be considered, depending on many factors. While one 2017 study found that mastectomy was associated with worse overall survival than lumpectomy among people with primary angiosarcoma, another 2017 study published in the New England Journal of Medicine suggests that mastectomy to obtain wide margins is often the treatment of choice with secondary angiosarcoma.

Unlike epithelial breast cancers, a sentinel node biopsy or axillary lymph node dissection is not usually done, as these tumors are much less likely to spread to regional lymph nodes.

Also, unlike most breast cancers, treatment following surgery to reduce the risk of recurrence (adjuvant therapy) does not appear to be effective.


Unlike the majority of breast cancers that arise in epithelial cells, breast angiosarcomas do not often respond to chemotherapy. That said, for some people, depending on the characteristics of the tumor, it may be helpful.

Radiation Therapy

As with chemotherapy, some people may receive radiation therapy depending on the characteristics of the tumor. On average, however, radiation does not appear to have any survival benefit for people with primary angiosarcoma, and may be associated with poorer survival in people with secondary angiosarcoma.

Clinical Trials

Fortunately, studies are looking at systemic therapies (therapies that treat a cancer anywhere in the body) for angiosarcoma.

One 2018 study notes treatment with VEGF inhibitors appears promising. VEGF inhibitors are a type of targeted therapy aimed at specific molecular abnormalities involved in the growth of cancer, and in general, have fewer side effects than chemotherapy.

Other treatments, such as a type of immunotherapy known as interleukin-2, anti-angiogenesis therapies (such as Avastin), and hyperthermia (using heat to kill cancer) are being studied in clinical trials.

Your Care Team

For people who have been diagnosed with angiosarcomas, seeking treatment (or a second opinion) at a major cancer center might improve outcomes.

A 2018 study in the British Journal of Surgery found that women with secondary angiosarcomas of the breast who were referred for specialty treatment (with a multidisciplinary team that manages sarcomas) had a lower recurrence rate and improved disease-specific survival.

Larger cancer centers, especially National Cancer Institute-designated centers, are more likely to have oncologists who specialize in sarcomas and have experience in treating people with this uncommon form of breast cancer.


While angiosarcomas are usually aggressive tumors, each one is different, and prognosis will depend on the stage at which it is diagnosed, how far it has spread at the time of diagnosis, and how aggressively it is treated.

Survival rates vary significantly among studies, but are better when the tumor can be surgically removed.

A Word From Verywell

Coping with an uncommon type of breast cancer can be challenging, as less is known and there are fewer survivors around to talk with. Fortunately, online support communities now allow people with uncommon and rare cancers the chance to communicate with others facing a similar journey around the globe.

As with any cancer, it's important to learn about your cancer and be your own advocate, but it is even more important with uncommon tumors. And with fewer specialists available who have experience in treating the disease, you may need to locate and travel to a high-volume cancer center to get the best care with the latest treatments and clinical trials.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Arora TK, Terracina KP, Soong J, Idowu MO, Takabe K. Primary and secondary angiosarcoma of the breast. Gland Surg. 2014;3(1):28-34. doi;10.3978/j.issn.2227-684X.2013.12.03

  2. Johns Hopkins Medicine. Angiosarcoma of the Breast.

  3. Cleveland Clinic. Breast Cancer. Updated December 31, 2018.

  4. Yin M, Wang W, Drabick JJ, Harold HA. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer. 2017;17(1):295. doi:10.1186/s12885-017-3292-7

  5. Arora TK, Terracina KP, Soong J, Idowu MO, Takabe K. Primary and secondary angiosarcoma of the breastGland Surg. 2014;3(1):28–34. doi:10.3978/j.issn.2227-684X.2013.12.03

  6. National Cancer Institute. Angiosarcoma. Updated February 27, 2019.

  7. Yin M, Wang W, Drabick JJ, Harold HA. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer. 2017;17(1):295. doi:10.1186/s12885-017-3292-7

  8. Plichta JK, Hughes K. Radiation-Induced Angiosarcoma after Breast-Cancer Treatment. N Engl J Med. 2017;376(4):367. doi:10.1056/NEJMicm1516482

  9. Yin M, Wang W, Drabick JJ, Harold HA. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative studyBMC Cancer. 2017;17(1):295. Published 2017 Apr 27. doi:10.1186/s12885-017-3292-7

  10. Lyou Y, Barber E, Mehta R, Lee T, Goreal W, Parajuli R. Radiation-Associated Angiosarcoma of the Breast: A Case Report and Literature Review. Case Rep Oncol. 2018;11(1):216-220. doi:10.1159/000488314

  11. Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapiesCancers (Basel). 2011;3(3):3279–3330. Published 2011 Aug 12. doi:10.3390/cancers3033279

  12. Feinberg L, Srinivasan A, Singh JK, et al. Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. Br J Surg. 2018;105(4):401-409. doi:10.1002/bjs.10696

  13. Choi JH, Ahn KC, Chang H, Minn KW, Jin US, Kim BJ. Surgical Treatment and Prognosis of Angiosarcoma of the Scalp: A Retrospective Analysis of 14 Patients in a Single InstitutionBiomed Res Int. 2015;2015:321896. doi:10.1155/2015/321896